The purpose of this study is to determine if treatment with a single dose of RE104 study drug for injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo. Postpartum Depression is a biological complication of pregnancy. Symptoms can be severe and shouldn’t be ignored.
CONTACT US ABOUT PPD TRIALPostpartum Depression
Description
Eligibility Criteria
18-45 Years Old; Gave birth within the last 12 months; Frequently feel extremely sad, anxious, or overwhelmed and these symptoms are associated with postpartum depression; The study doctor will discuss other requirements.
Duration
Up to 8 weeks total (including Screening and Safety Follow-up Periods)
Intervention
Single, subcutaneous dose of RE104 for Injection